A Study of Quality of Life Assessment Using the KDQOL-SF™ Scale in Patients with Renal Disease Undergoing Rheocarna^®

Abstract

We aimed to evaluate the quality of life（QOL）of chronic limb-threatening ischemia（CLTI）patients treated with Rheocarna® and to examine changes in QOL after Rheocarna® treatment. We performed blood purification therapy with Rheocarna® for CLTI in patients with end-stage renal disease（ESRD）.
 The research design was a survey using the Kidney Disease Quality of Life Short Form version 1.3, a self-administered questionnaire that is validated and widely used to measure QOL in patients with ESRD.
 The subjects were 14 patients who received Rheocarna® treatment between June 21, 2021, and May 30, 2023. We found that CLTI patients had lower comprehensive QOL, particularly in terms of bodily pain, compared to representative values. On the other hand, renal disease-specific QOL was better than representative values, except for the “burden of renal disease.”
 After treatment with Rheocarna®, significant improvements were observed in the comprehensive QOL categories of “bodily pain,” “social functioning,” and “vitality”（p<0.05）.
 These findings suggest that the alleviation of pain symptoms by Rheocarna® treatment leads to other QOL improvements in ESRD patients.